Abstract:Objectives
Treatment of patients with rheumatoid arthritis (RA) has improved markedly over the past 25 years. We investigated if rates of joint surgery, a long-term consequence of poorly-controlled RA, have changed over this period.
Methods
In this population-based, serial cross-sectional study of patients aged ≥ 40 years with RA in California, we examined trends in annual rates of total knee arthroplasty, total hip arthroplasty, total ankle arthroplasty or arthrodesis, and total wrist arthroplasty or arthro… Show more
“…In a sense, total joint replacement represents the failure of medical treatment to control RA adequately, and the incidence of total joint replacement is a measure of disease progression and the ineffectiveness of treatment (14). The incidence of total joint replacement decreases with time, likely due to advances in RA treatment with MTX and biologic DMARDs (23)(24)(25)(26)(27). A previous study suggested that in order to inhibit the need for total joint replacement in patients treated with TNF inhibitors, it is important to maintain tight control over RA activity (28).…”
Objective. To determine the effects of concomitant methotrexate (MTX) on the incidence of large joint replacement resulting from the progression of large joint destruction in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors. Methods. A retrospective cohort study was performed using a multicenter registry. In total, 803 patients with RA who received etanercept or adalimumab were included. The first large joint replacement during treatment with etanercept or adalimumab was used as the outcome variable in predictive analyses. The cumulative incidence of large joint replacement was estimated using Kaplan-Meier curves, and the impact of concomitant MTX on the incidence of large joint replacement was assessed with Cox proportional hazards models. Propensity score matching was used to reduce selection bias. Results. Of all patients, 601 (75%) received concomitant MTX at a median dosage of 8 mg/week (interquartile range 6-8). A total of 49 patients (62 joints) underwent large joint replacement during treatment with etanercept or adalimumab. The incidence of large joint replacement for patients with concomitant MTX was significantly lower than that for patients without MTX (P < 0.001). Multivariate analysis revealed that concomitant MTX independently predicted large joint replacement (hazard ratio 0.36, 95% confidence interval 0.20-0.65). Additionally, propensity score-matched analysis demonstrated that patients with concomitant MTX had a significantly lower incidence of large joint replacement than those without concomitant MTX (P 5 0.032). Conclusion. Concomitant MTX reduces the incidence of large joint replacement in patients with RA treated with TNF inhibitors.
“…In a sense, total joint replacement represents the failure of medical treatment to control RA adequately, and the incidence of total joint replacement is a measure of disease progression and the ineffectiveness of treatment (14). The incidence of total joint replacement decreases with time, likely due to advances in RA treatment with MTX and biologic DMARDs (23)(24)(25)(26)(27). A previous study suggested that in order to inhibit the need for total joint replacement in patients treated with TNF inhibitors, it is important to maintain tight control over RA activity (28).…”
Objective. To determine the effects of concomitant methotrexate (MTX) on the incidence of large joint replacement resulting from the progression of large joint destruction in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors. Methods. A retrospective cohort study was performed using a multicenter registry. In total, 803 patients with RA who received etanercept or adalimumab were included. The first large joint replacement during treatment with etanercept or adalimumab was used as the outcome variable in predictive analyses. The cumulative incidence of large joint replacement was estimated using Kaplan-Meier curves, and the impact of concomitant MTX on the incidence of large joint replacement was assessed with Cox proportional hazards models. Propensity score matching was used to reduce selection bias. Results. Of all patients, 601 (75%) received concomitant MTX at a median dosage of 8 mg/week (interquartile range 6-8). A total of 49 patients (62 joints) underwent large joint replacement during treatment with etanercept or adalimumab. The incidence of large joint replacement for patients with concomitant MTX was significantly lower than that for patients without MTX (P < 0.001). Multivariate analysis revealed that concomitant MTX independently predicted large joint replacement (hazard ratio 0.36, 95% confidence interval 0.20-0.65). Additionally, propensity score-matched analysis demonstrated that patients with concomitant MTX had a significantly lower incidence of large joint replacement than those without concomitant MTX (P 5 0.032). Conclusion. Concomitant MTX reduces the incidence of large joint replacement in patients with RA treated with TNF inhibitors.
“…Previous studies have shown a reduction in the rates of orthopaedic joint arthroplasty for rheumatoid patients [8,11,12,18,23] as well as a recent study that highlights the apparent decline of hand surgery for patients with RA [5].…”
Background Rheumatoid arthritis (RA) is the most common idiopathic inflammatory arthritis affecting 0.8 % of the population. It can cause significant hand and wrist damage and dysfunction. Recent advances in anti-rheumatic treatments have the potential to decrease the prevalence of hand deformities in patients with RA.
“…In a study of Californian adults over two decades Louie et al 2010 [13] noted that the demand for knee arthroplasty decreased in younger patients, and paralleled the general population requirements in older patients. The introduction of the use of methotrexate in the 1970s, and more recently the use of Tumour Necrosis Factor α has been attributed to milder forms of the disease and the slowing of radiographic deterioration [14].…”
Section: Incidence / Prevalencementioning
confidence: 99%
“…Without appropriate pharmacological treatment or surgical intervention it can lead to profound disability and pain. The evolution of disease modifying anti-rheumatoid drugs (DMARDs) has had a significant effect on the number of patients requiring surgery [13].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.